Rhizoma Drynariae protects against Canaglifloxacin induced bone loss
| Autor: | Kalpana Krishnaraju, Khalid A Asseri, Krishnaraju Venkatesan, Kumar Venkatesan, Sirajudeen Shaik Alavudeen, Ester Mary Pappiya, R. Natarajan, Kumarappan Chidambaram, Noohu Abdulla Khan, Yahya I. Asiri, Ali Alqahtani, Premalatha Paulsamy |
|---|---|
| Rok vydání: | 2021 |
| Předmět: | |
| Zdroj: | International Journal of Current Research in Chemistry and Pharmaceutical sciences. 8:22-28 |
| ISSN: | 2348-5221 2348-5213 |
| DOI: | 10.22192/ijcrcps.2021.08.09.004 |
| Popis: | Osteoporosis is a condition marked by a loss of bone mass and degradation of the bone microstructure, both of which lead to increased fragility and consequent fragility fractures, particularly in the elderly. Rhizoma Drynariae (DRE) is one of the most often used herbal remedies for osteoporosis therapy. Transdermal drug administration is a well- established new method for drug delivery that offers numerous benefits over conventional routes. Wistar albino rats were split into five groups of six rats each: vehicle control, diabeticgroup, DRE group, Canagliflozin (CGF), and CGF + DRE group. Each medication was given by gastric gavage once a day for 35 days. The drug canagliflozin appears to raise the risk of fractur. When compared to the control group, DRE treatment increased bone strength at the femoral diaphysis in osteoporotic fractures in rats by increasing ultimate load and stiffness. The goal of this study is to investigate the anti-osteoporosis effects of DRE in diabetic rats co-treated with CGF. Blood glucose levels and bone mineral density (BMD) were measured. According to the data, DRE produced a significant increase in bone amount. DRE may help prevent and cure diabetic osteoporosis by increasing bone mineral density, according to one study. Keywords: Rhizoma Drynariae Diabetic osteoporosis, Streptozotocin induced diabetes, Canagliflozin |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|